VitaDX (Rennes) has managed to raise €1.5M from private investors to develop its innovative technology for early, non-invasive detection of bladder cancer. “Disruptive”, the technology aims to “become the gold standard of early bladder cancer diagnosis”, if the director of the company is to be believed. The company has an exclusive global licence for the exploitation of its patent. Note that VitaDX intends to extend it to other cytologies: pleural fluid for lung cancer, ascites for cancer of the digestive tract and cerebral fluid for cancer of the cerebral system. The company should shortly open two subsidiaries in the USA and Asia in anticipation of major international development.
Sources : API newsletter – 24/02/2016
Photo credit : vitadx.com
For further information, contact us at firstname.lastname@example.org